This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

Lysogene Future Growth

Future criteria checks 0/6

We currently don't have sufficient analyst coverage to forecast growth and revenue for Lysogene.

Key information

n/a

Earnings growth rate

n/a

EPS growth rate

Biotechs earnings growth	5.0%
Revenue growth rate	n/a
Future return on equity	n/a
Analyst coverage	None
Last updated	n/a

Recent future growth updates

Breakeven On The Horizon For Lysogene S.A. (EPA:LYS)

May 05

Recent updates

Breakeven On The Horizon For Lysogene S.A. (EPA:LYS)

May 05

Lysogene (EPA:LYS) Shareholders Have Enjoyed A 5.9% Share Price Gain

Feb 17

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Lysogene has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.

Earnings and Revenue Growth Forecasts

ENXTPA:LYS - Analysts future estimates and past financials data (EUR Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
6/30/2022	13	-7	-14	-13	N/A
3/31/2022	10	-10	-14	-14	N/A
12/31/2021	7	-14	-15	-14	N/A
9/30/2021	9	-12	N/A	N/A	N/A
6/30/2021	10	-11	-13	-13	N/A
3/31/2021	13	-8	-14	-14	N/A
12/31/2020	16	-5	-15	-14	N/A
9/30/2020	18	-4	N/A	N/A	N/A
6/30/2020	19	-2	-18	-17	N/A
3/31/2020	18	-3	-8	-7	N/A
12/31/2019	17	-4	2	2	N/A
9/30/2019	15	-5	13	14	N/A
6/30/2019	13	-6	25	25	N/A
3/31/2019	9	-8	17	17	N/A
12/31/2018	6	-11	9	9	N/A
9/30/2018	4	-14	-2	-2	N/A
6/30/2018	3	-17	-13	-13	N/A
3/31/2018	3	-17	-14	-14	N/A
12/31/2017	3	-18	-15	-15	N/A
9/30/2017	2	-15	-13	-13	N/A
6/30/2017	2	-13	-10	-10	N/A
3/31/2017	2	-10	-8	-8	N/A
12/31/2016	1	-7	-7	-7	N/A
9/30/2016	1	-6	-6	-6	N/A
6/30/2016	1	-5	-6	-6	N/A
3/31/2016	1	-5	N/A	-4	N/A
12/31/2015	0	-4	N/A	-3	N/A
12/31/2014	1	-1	N/A	-2	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: Insufficient data to determine if LYS's forecast earnings growth is above the savings rate (0.6%).

Earnings vs Market: Insufficient data to determine if LYS's earnings are forecast to grow faster than the French market

High Growth Earnings: Insufficient data to determine if LYS's earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: Insufficient data to determine if LYS's revenue is forecast to grow faster than the French market.

High Growth Revenue: Insufficient data to determine if LYS's revenue is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if LYS's Return on Equity is forecast to be high in 3 years time

This company listing is no longer active

Lysogene Future Growth

Future criteria checks 0/6

Key information

Recent future growth updates

Price target increased to €11.00

Price target increased to €11.00

Breakeven On The Horizon For Lysogene S.A. (EPA:LYS)

Recent updates

Lysogene Announces to Delist from Euronext

Lysogene Appoints Côme de La Tour du Pin as Chief Financial Officer

Lysogene Provides Updates and Topline Results from Phase 2/3 Aavance Gene Therapy Clinical Study

Price target increased to €11.00

First half 2022 earnings released: EPS: €0.04 (vs €0.33 loss in 1H 2021)

Lysogene Announces New Board of Directors

Lysogene Provides Additional Update on Aavance Phase 2/3 Gene Therapy Clinical Trial with LYS-SAF302 in Children with MMPS IIIA

Lysogene S.A. Provides Clinical Update on AAvance Phase 2/3 Clinical Trial with Gene Therapy LYS-SAF302 for the Treatment of MPS IIIA At the 25Th Annual ASGCT Meeting

Price target increased to €11.00

Full year 2021 earnings: Revenues exceed analysts expectations while EPS lags behind

Lysogene Provides Update on Efficacy, Safety and Timelines of the AAVance Phase 2/3 Clinical Trial with Gene Therapy LYS-SAF302 for the Treatment of Mpsiiia

Lysogene Reports Additional Positive Biomarker Data With LYS-SAF302 and Favorable Safety Data With LYS-GM101

Lysogene S.A. Provides Medical Update

Lysogene S.A. announced that it has received €4.3 million in funding from Bpifrance Investissement SAS

First half 2021 earnings released: €0.33 loss per share (vs €0.015 profit in 1H 2020)

Lysogene Announces First Patient in the United States Dosed with LYS-GM101 Investigational Gene Therapy for the Treatment of GM1 Gangliosidosis

Lysogene Announces First Patient Dosed with LYS-GM101 Investigational Gene Therapy for the Treatment of GM1 Gangliosidosis

Lysogene Announces Phase 3 Gene Therapy Platform Company Targeting Central Nervous System Diseases

Breakeven On The Horizon For Lysogene S.A. (EPA:LYS)

Full year 2020 earnings released: €0.32 loss per share (vs €0.32 loss in FY 2019)

Lysogene (EPA:LYS) Shareholders Have Enjoyed A 5.9% Share Price Gain

Lysogene Reports LYS-SAF302 Biomarker Data Presented at the WORLDSymposium 2021

Lysogene S.A. Receives FDA Clearance of Investigational New Drug Application to Initiate the Gene Therapy Clinical Trial in the US with Lys-Gm101 for the Treatment of Gm1 Gangliosidosis

New 90-day high: €3.26

Lysogene S.A., Annual General Meeting, Jun 25, 2021

Lysogene Receives MHRA and Research Ethics Committee Approvals to Initiate the Gene Therapy Clinical Trial in the UK with LYS-GM101 for the Treatment of GM1 Gangliosidosis

New 90-day high: €2.65

Lysogene Reports Positive Biomarker Data With LYS-SAF302

New 90-day low: €2.06

Lysogene Provides Update on the AAVance Clinical Trial Evaluating Lys-Saf302 in Patients with MPS IIIA

New 90-day low: €2.07

First half earnings released

New 90-day low - €2.10

New 90-day low - €2.39

Earnings and Revenue Growth Forecasts

Analyst Future Growth Forecasts

Earnings per Share Growth Forecasts

Future Return on Equity

Discover growth companies